An in vitro study showed that knockdown of HMGB1 alleviated upregulation of NF-κB signaling and inflammatory responses; therefore, anti-HMGB1 monoclonal antibody therapy should be considered as a potential treatment strategy for PD (Nishibori et al., 2019; Huang et al., 2020). Here, HMGB1 is linked to Parkinson disease.